Capricor TherapeuticsCAPR just hit that mark, with a jump from 69 to 86 Thursday. Please watch the video at Investors.com - ...

Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are ...

Fintel reports that on June 26, 2025, B. Riley Securities initiated coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a Buy recommendation. Analyst Price Forecast Suggests 327.54% Upside As of ...

Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, provided regulatory updates related to its Biologics License Application ...

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Capricor Therapeutics CAPR shares ended the last trading session 20.4% higher at $9.25. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Capricor on Tuesday disclosed that the FDA has indicated that no AdCom is necessary for deramiocel’s Biologics License Application, and an in-person late-cycle review meeting is scheduled for ...